Navigation Links
Generex Provides Clarification of Facts
Date:6/27/2011

e on a comprehensive strategy to achieve FDA approval of Generex Oral-lyn™.  Today, Dr. Anderson, an independent member of the Generex Board, commented:  "The Company's scientific team is confident that our clinical and regulatory program is designed for success, and we intend to conduct a broader study to include a wider patient population in both type 1 and type 2 diabetes."  The full presentation from the annual meeting of stockholders' is available for viewing on the Generex website at www.generex.com.

Mark Fletcher, Generex President & Chief Executive Officer, stated:  "We have made great strides in establishing  a top notch scientific team at Generex and, as a result, have established a realistic and focused plan to realize success in the future for the largest possible patient population.  The closing of the current Phase III study and the data we obtain from it will further that effort.  Generex Oral-lyn™ has demonstrated efficacy and safety in all of the studies conducted to date."

The June 16 Generex press release stated that the Company's clinical and regulatory plan for Generex Oral-lyn™ will "focus on rapid registration in the North American major markets, with its rapid absorption and sharp peak in plasma insulin concentration mimicking normal insulin secretion, and Generex Oral-lyn™'s short duration of activity reducing the potential for hypoglycemia.  Studies will include a key activity/effect (pharmokinetic/glucodynamic) study using the final formulation and a series of small, well-designed phase 3 studies (potentially conducted as one study with multiple arms)."  Generex management anticipates that these studies will be completed during 2013.  Generex will also focus on studies that will measure Generex Oral-lyn™'s ability to provide metabolic benefits that cannot be achieved with subcutaneously inj
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Results of Annual Stockholders Meeting
2. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
3. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
4. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
5. Generex Announces $3.0 Million Capital Investment
6. Generex Provides Additional Details for October 21st Live Video Webcast
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
10. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... 10, 2014 Robert Harman, DVM, Founder and ... is proud to announce the relaunch of his highly informative ... new series called “ What are Stem Cells ?” ... and straightforward foundation in the basics of stem cell therapy ... the right type of treatment when considering regenerative medicine. , ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... ... WILMINGTON, Del., April 22 , Highlights -- First quarter 2008 ... year. Excluding a significant item charge in the prior year, earnings ... 6 percent higher local selling prices and 5 percent currency benefit, ...
... Step to Tap Alternative Energy Business in China, ... Technology,Company Ltd ("JIC" or "the Company") to be ... 987), a wholly-owned subsidiary of HKC,(Holdings) Limited ("HKC ... invest in three alternative energy projects at the ...
... Ortho Evra is an adhesive,transdermal birth control patch. It ... of ethinyl estradiol into the bloodstream per 24,hours. It is ... is worn,during the fourth week. Ortho Evra was approved by ... used Ortho Evra since its approval.,Ortho Evra continues to be ...
Cached Biology Technology:DuPont Reports First Quarter Earnings Growth of Over 20 Percent 2DuPont Reports First Quarter Earnings Growth of Over 20 Percent 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 4DuPont Reports First Quarter Earnings Growth of Over 20 Percent 5DuPont Reports First Quarter Earnings Growth of Over 20 Percent 6DuPont Reports First Quarter Earnings Growth of Over 20 Percent 7DuPont Reports First Quarter Earnings Growth of Over 20 Percent 8DuPont Reports First Quarter Earnings Growth of Over 20 Percent 9DuPont Reports First Quarter Earnings Growth of Over 20 Percent 10DuPont Reports First Quarter Earnings Growth of Over 20 Percent 11DuPont Reports First Quarter Earnings Growth of Over 20 Percent 12DuPont Reports First Quarter Earnings Growth of Over 20 Percent 13DuPont Reports First Quarter Earnings Growth of Over 20 Percent 14DuPont Reports First Quarter Earnings Growth of Over 20 Percent 15DuPont Reports First Quarter Earnings Growth of Over 20 Percent 16DuPont Reports First Quarter Earnings Growth of Over 20 Percent 17DuPont Reports First Quarter Earnings Growth of Over 20 Percent 18JIC Invests in Three New Alternative Energy Projects 2JIC Invests in Three New Alternative Energy Projects 3JIC Invests in Three New Alternative Energy Projects 4JIC Invests in Three New Alternative Energy Projects 5Ortho Evra Patch Makers Settling Cases 2
(Date:7/11/2014)... news release is available in German . ... is a method that uses the refraction of X-rays ... The images produced with this method are often of ... scientists in the team of Prof. Franz Pfeiffer are ... imaging and therapy including X-ray phase-contrast imaging. One ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2BGI reports a novel gene for salt tolerance found in wild soybean 2A first direct glimpse of photosynthesis in action 2
... that causes plaque buildup in Alzheimer,s disease is the focus ... Georgia Health Sciences University graduate student. In Alzheimer,s, the ... eliminated by the body,s natural defenses, nestling between the neurons ... gets there could be targets for a new vaccine. ...
... Sept. 26, 2011 -A compound tested by UT Southwestern Medical ... that killed an estimated 30 million people in the worldwide ... by increasing the levels of a human antiviral protein - ... the flu, a virus that tends to mutate into strains ...
... Scientists have for the first time discovered sixteen new sections ... opening up the possibility for better prevention as well ... 175 scientists from 126 centres in Europe, the USA and ... human lung. Their discovery sheds new light on the ...
Cached Biology News:Award-winning research points toward Alzheimer’s vaccine 2Compound kills highly contagious flu strain by activating antiviral protein 2New discoveries in genetics of lung health 2
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: